Syndax Pharmaceuticals' stock surged 5.04% during intraday trading on Friday, reflecting strong investor interest in the pharmaceutical company.
The price movement appears to be driven by positive analyst sentiment, with H.C. Wainwright analyst Andres Y. Maldonado reiterating a Buy rating on the company and setting a price target of $40.00. Such analyst endorsements often generate increased investor confidence and buying activity in the market.